Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178017 · ClinicalTrials.gov registry record · NA
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
A NA study of IBS - Irritable Bowel Syndrome, sponsored by Oxford Biomedical Technologies.
- Active
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05178017: Active NA study of IBS - Irritable Bowel Syndrome, sponsored by Oxford Biomedical Technologies.
NCT05178017 is a NA study of IBS - Irritable Bowel Syndrome that is active but no longer recruiting, run by Oxford Biomedical Technologies. The registered enrollment target is 60 participants, below the 73-participant average among 6 other IBS - Irritable Bowel Syndrome trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05178017, a NA study of IBS - Irritable Bowel Syndrome, is active but no longer recruiting, sponsored by Oxford Biomedical Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.
Primary Outcome
To evaluate the cytokines levels (IL-I b; IL-6; IL-8; IL-10; IL-12; IL-17; TNF-a) of participants with irritable bowel syndrome from baseline levels to 12 weeks by using a Bio-Plex 200 System (Bio-Rad, California, USA).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program
Study Locations (1)
Florida
- Oxford Biomedical Technologies, Inc. - Riviera Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT05178017 still lists
NCT05178017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 73-participant average among 6 other IBS - Irritable Bowel Syndrome trials with a reported enrollment target (18% lower).
The record links to 1 condition, with IBS - Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program is the first listed.
NCT05178017 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05178017 about?
NCT05178017 is a clinical study titled "Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)". A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.
What is the current status of trial NCT05178017?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2021-09-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05178017 study?
This clinical trial studies the following conditions: IBS - Irritable Bowel Syndrome.
What interventions are being tested in trial NCT05178017?
The interventions under investigation include: Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05178017?
This trial is sponsored by Oxford Biomedical Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05178017 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IBS - Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Relaxation Music for Chronic Pain
ACTIVE NOT RECRUITING · NA
-
Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms
COMPLETED · NA
-
The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
RECRUITING · Phase 2
-
Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
RECRUITING
-
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
RECRUITING
-
Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI